The mission of the North Central Cancer Treatment Group (NCCTG) is to improve the duration and quality of life of cancer patients by performing high-quality clinical and translational research in the community setting. NCCTG was founded on the premise that cancer care in the U.S. occurs primarily in the community practice setting. Consequently, the community is the most appropriate venue for testing novel approaches to prevention, diagnosis, treatment, and symptomatic management of cancer. Since 2003, NCCTG has received more than 17,000 tumor tissue blocks from over 12,000 patients, and NCCTG has received over 38,000 body fluid biospecimens from more than 9,500 patients. Typically, specimens are received from 70 to 90% of patients from whom they are requested, and approximately 75% originate from community oncology sites. Consequently, specimens representative of the clinical trial participants are available in sufficient numbers to answer the scientific questions posed in the correlative laboratory studies. The NCCTG Biospecimen Resource will support the NCCTG mission by providing superior biospecimens from patients enrolled on NCCTG trials that 1) are fully and consistently annotated, 2) have been collected under optimized standard conditions, 3) have undergone quality assessment, and 4) are stored under controlled conditions allowing efficient retrieval for distribution to qualified researchers. The four specific aims of this application are: 1) to continue to optimize the collection and annotation of biospecimens obtained from patients enrolled on NCCTG and other cooperative group clinical trials;2) to maintain standard operating procedures (SOPs) for collecting, processing and storing biospecimens;3) to apply emerging technologies for collection and processing of biospecimens;and 4) to provide ongoing oversight to the resource and Improve marketing and education regarding access to the resource for the research community. NCCTG representatives will actively participate in Group Banking Committee (GBC) activities, will assume leadership roles within the GBC as appropriate, and will implement policies established by the GBC. NCCTG is committed to harmonization of GBC processes, including standard operating procedures, promotion of the resource, information systems, and development of new strategies during the proposed

Public Health Relevance

The NCCTG Biospecimen Resource provides large numbers of well-annotated biospecimens from patients enrolled in specified treatment protocols with definitive endpoints, thus, enabling research in markers diagnostic of a particular disease entity, prognostic of disease progression or predictive of response to treatment. Appropriate and efficient use of this resource is vital to promote the scientific mission of NCCTG, other cooperative groups, and the national research agenda for cancer prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA114740-08
Application #
8459888
Study Section
Special Emphasis Panel (ZCA1-SRLB-5 (M1))
Program Officer
Lubensky, Irina
Project Start
2005-08-17
Project End
2014-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
8
Fiscal Year
2013
Total Cost
$838,814
Indirect Cost
$306,909
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Reinholz, Monica M; Chen, Beiyun; Dueck, Amylou C et al. (2017) IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res 23:4203-4211
Lee, Adam M; Shi, Qian; Alberts, Steven R et al. (2016) Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 26:133-7
Perez, Edith A; Thompson, E Aubrey; Ballman, Karla V et al. (2015) Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 33:701-8
Yoon, Harry H; Shi, Qian; Alberts, Steven R et al. (2015) Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst 107:
Perez-Carbonell, L; Sinicrope, F A; Alberts, S R et al. (2015) MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer 113:83-90
Sinicrope, Frank A; Shi, Qian; Smyrk, Thomas C et al. (2015) Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148:88-99
Zhu, Shijun; Kisiel, Walter; Lu, Yang J et al. (2015) Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target 23:257-65
Sinicrope, Frank A; Mahoney, Michelle R; Yoon, Harry H et al. (2015) Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res 21:5294-304

Showing the most recent 10 out of 49 publications